- Home
- YI vs CALC Comparison
YI vs CALC Comparison
Compare YI & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YI
- CALC
- Stock Information
- Founded
- YI 2010
- CALC 2011
- Country
- YI China
- CALC United States
- Employees
- YI N/A
- CALC N/A
- Industry
- YI Retail-Drug Stores and Proprietary Stores
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- YI Consumer Staples
- CALC Health Care
- Exchange
- YI Nasdaq
- CALC Nasdaq
- Market Cap
- YI 38.1M
- CALC 45.4M
- IPO Year
- YI N/A
- CALC N/A
- Fundamental
- Price
- YI $4.34
- CALC $3.00
- Analyst Decision
- YI
- CALC Strong Buy
- Analyst Count
- YI 0
- CALC 2
- Target Price
- YI N/A
- CALC $14.50
- AVG Volume (30 Days)
- YI 10.3K
- CALC 40.6K
- Earning Date
- YI 11-26-2025
- CALC 11-07-2025
- Dividend Yield
- YI N/A
- CALC N/A
- EPS Growth
- YI N/A
- CALC N/A
- EPS
- YI N/A
- CALC N/A
- Revenue
- YI $1,979,883,442.00
- CALC N/A
- Revenue This Year
- YI N/A
- CALC N/A
- Revenue Next Year
- YI N/A
- CALC N/A
- P/E Ratio
- YI N/A
- CALC N/A
- Revenue Growth
- YI N/A
- CALC N/A
- 52 Week Low
- YI $4.15
- CALC $1.42
- 52 Week High
- YI $11.35
- CALC $4.26
- Technical
- Relative Strength Index (RSI)
- YI 37.45
- CALC 45.74
- Support Level
- YI $4.20
- CALC $2.95
- Resistance Level
- YI $4.43
- CALC $3.13
- Average True Range (ATR)
- YI 0.16
- CALC 0.14
- MACD
- YI 0.05
- CALC -0.01
- Stochastic Oscillator
- YI 23.28
- CALC 15.97
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.